Supplementary Materials

The PDF file includes:

  • Fig. S1. Defects in Jak1 or Jak2 do not alter sensitivity of irradiated B16 tumors to irradiation and dual ICB.
  • Fig. S2 CRISPR modifications of B16 tumor cell lines do not alter gp100 expression.
  • Fig. S3. MHC I expression of human melanoma exhibits IFN-α dependence.
  • Fig. S4. MHC I expression of human melanoma exhibits IFN-β dependence.
  • Fig. S5. Gating strategy to assess in vivo MHC I expression of B16-F10.
  • Fig. S6. Nlrc5 overexpression does not augment the antitumor efficacy of adoptively transferred pmel T cells against B16-WT tumors.
  • Fig. S7. BO-112 augments the efficacy of pmel T cells against B16-WT tumors in vivo.
  • Fig. S8. BO-112 and pmel ACT alter the immune composition of B16-Jak1KO tumors.
  • Fig. S9. B16-B2mKO tumor cells are resistant to killing by pmel T cells.
  • Fig. S10. BO-112–induced MHC I up-regulation in B16-Jak1KO cell lines is Nlrc5 independent.
  • Fig. S11. BO-112 induces cytoplasmic phosphorylation and nuclear translocation of NF-κB (p65) in B16-Jak1KO cells.
  • Fig. S12. Protein-level effects of siRNA targeting Ifih1, Ddx58, or Tlr3.
  • Table S1. CRISPR guides and RT-PCR primer sequences.
  • Table S2. Reagents.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: